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I.INTRODUCTION: 
Head and neck cancer is the sixth most common cancer worldwide.(1) 
50% of the overall global head and neck cancer burden is from Asia, India in 
specific. (2)Each year 2 lakhs new patients are diagnosed and 1 lakh patient die 
with oral cavity cancers.(3) In India carcinoma buccal mucosa and carcinoma 
tongue are more common among the oral cavity cancers. Carcinoma tongue is 
second most common cancer of oral cavity. It is more common in men 
compared to women. The ratio is 3:1 in sex distribution.(4) The incidence of 
carcinoma tongue according to Madras Metropolitan Tumour Registry (MMTR) 
is 10.3 /100000 population for the year 2012-13. (5) 
Incidence rates for the year 2012-13. 
Source Sex CIR ASR No of cases Total cases 
World GLOBOCAN 
(Oral cavity) 
Male 5.6 5.5 198975 7410376 
Female 2.9 2.5 101398 6657518 
India IARC 
(Oral cavity) 
Male 8.3 10.1 53842 477482 
Female 3.8 4.3 23161 537452 
Chennai MMTR 
(Tongue) 
Male 8.1 7.4 380 5448 
Female 2.2 2.0 101 6219 
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1).INSTITUTE DATA 
609 patients presenting to the Institute from 2006 to 2011 are diagnosed 
with carcinoma tongue. Most of the patients report to the institute in locally 
advanced stages. Stage wise 5 years Disease free survival (DFS) and 5 year 
Overall survival (OS) is given below. 
Stage Total cases DFS 5 years OS 
I 87 52% 74% 
II 122 36% 50% 
III 160 40% 46% 
IV 237 19% 23% 
 
5years Relative survival of Oral cancer (1988-2001) from SEER database (6). 
 
 
 Tongue (%) Oral Tongue (%) 
Stage I 70.7 75.9 
Stage II 58.6 57.5 
Stage III 47.3 38.8 
Stage IV 36.7 26.5 
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Distribution of treatment modalities used in our institute from 2006 -11  
 
Treatment modality No of cases Percentage 
Concurrent chemo-radiation 327 54% 
Radiation alone 170 28% 
Surgery followed adjuvant Radiation 58 9.5% 
Surgery followed by concurrent chemo-
radiation 
36 6% 
Surgery alone 16 2.5% 
Surgery followed by chemotherapy 1 <0.2% 
Palliative chemotherapy 1 <0.2% 
Total 609  
 
5 Years DFS and 5 years OS with concurrent chemo-radiation and Radiation 
alone are given below. 
 
Treatment DFS 5 years OS 
RT+CT 30% 38% 
RT alone 36% 19% 
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2).RISK FACTORS FOR TONGUE CANCER:  
The common causes for tongue cancer are 
Five S’s 
Smoking  
Spirit (alcohol) 
Sharp (Septic) tooth 
Spicy food 
Syphilis 
 SMOKING AND ALCOHOL: 
Use of tobacco and alcohol is associated with 80-90% of all case of 
carcinoma tongue. A Case control study with two arms, smoking alone and 
smoking along with alcohol showed that smoking increases the risk of 
developing cancer by about 25 times than in non-smokers.(7) Tobacco in any 
form increases the risk of development tongue cancer by three folds. Both 
smoking and alcohol have synergistic effect and will increase incidence of 
cancers. Stopping smoking for more than 9 years will decrease the incidence of 
oral cancer by about 50 %(8). Second primary is more common in patients who 
smoke. Continuation of smoking during treatment results in a poor outcome. 
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Carcinogen in Tobacco: 
Aromatic hydrocarbons benzopyrene,  
Tobacco specific nitrosamines (TSNs),  
N-nitrosononicotine (NNN),  
N-nitrosopyrrolidine (NPYR),  
N-nitrosodimethylamine (NDMA),  
4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK). 
 
Mechanisms of tobacco carcinogenesis: 
These products will act on ketatinocyte stem cells. They produce DNA 
adducts (O-6-methylguanine) which interfere and disrupt the accuracy of DNA 
replication producing mutations, Leading to chromosomal instability. (9) 
 
Mechanisms of alcohol synergism: 
1) Alcohol increases the permeability of carcinogens in oral mucosa 
2) It will produce poor oral hygiene. 
3) It will reduce detoxification in liver for active carcinogens 
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NON SMOKING CAUSE OF ORAL CANCERS:  
DIETARY  
OCCUPATIONAL  
ENVIRONMENTAL 
LICHEN PLANUS: 
It will progress to malignant transformation in around about 0.3% 
patients. It is also associated with tobacco usage. 
GRAFT VERUS HOST DISEASE 
VIRUS: 
1) Human papilloma virus (HPV):   
 Up to 20% of oral cavity cancer shows HPV 16 DNA. 
2) HIV infection 
3) Herpes simplex virus(HSV) 
4) Epstein-barr virus(EBV) 
5) Hepatitis C virus.(HCV) 
 
Fungal infection:  
Candida albicans produce leucoplakia than may show malignant transformation. 
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CANCER SYNDROMES associated with carcinoma tongue 
Xeroderma pigmentosum 
Ataxia telangiectasia 
Li fraumeni syndrome  
Fanconi’s anemia 
NATURAL HISTORY:   
 
Patients most commonly present with chronic non healing ulcer with or 
without pain, young women may present with white patch-leukoplakia. Also 
difficulty in speech and swallowing. Tongue cancers grow rapidly either 
infiltrative or exophytic. Infiltrative tumours may be very large at presentation. 
Thick tumours have worse prognosis. Thickness >4 mm increased probability of 
occult metastasis to neck nodes.(10) 
Cytological 
Atypia 
Hyperplasia 
Dysplasia 
Carcinoma in 
situ 
Premalignant lession 
Invasive carcinoma  
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3).HISTOPATHOLOGY:  
Squamous cell carcinoma:  
It is most common. Seen in 90% cases. It has several variants, mostly 
Basaloid and verrucous carcinoma.(11) 
Basaloid squamous cell carcinoma: 
It has worse prognosis than normal squamous cell carcinoma. It is 
associated with advance disease, distant metastasis and poor overall survival. 
Verrucous squamous cell carcinoma: 
It is less common variant. It is a low grade malignancy with good local control 
and good overall survival. It presents as a thickened white patchy mucosa in 
early stages. But in advanced stage it looks like velvety exophytic lesion. 
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Treatment is excision of the lesion but it is prone to recur after excision. 
 
Non squamous cell carcinoma: 
Adenocarcinoma, 
Melanoma,  
Lymphoma,  
Leiomyosarcoma,   
Kaposi’s sarcoma.-mostly in oral cavity (gingiva, palate and tongue). After 
HAART treatment incidence decreased into 50% 
Adenosquamous carcinoma,  
Papillary squamous cell carcinoma, 
Sarcomatoid carcinoma 
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Prognostic factors in histology: 
1) Tumour margins 
2) Perineural invasion 
3) Histopathology of tumour 
4) Grade of tumour 
5) Lymphatic/vascular invasion 
6) Angiogenesis. 
   
 
4).PREMALIGNANT LESSIONS:  
Leukoplakia:  
It has two types homogenous and nonhomogenous. 
Homogenous: uniform white lesion and low (<1%) malignant potential. 
Non homogenous: nodular, sparkled lesion with central ulceration. It has more 
malignant potential. It has 18 % progress to cancer.(12) 
Leukoplakia will regress spontaneously no treatment needed. Need to do 
biopsy for malignant transformation. If it shows dysplatic changes we have to 
do excision of the lesion. Leukoplakia will occur 6 folds more in smokers 
compared to non-smokers 
Oral hairy leukoplakia:  
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It is due to virus infection of oral cavity. Malignant transformation is less 
common. 
Erythroplakia:   
It is chronic red patch on the mucosa. If erythroplakia is present we have 
find out other erythematous lesion in the patient. It has very high potential for 
malignant transformation compare to other pre malignant lesions. Erythroplakia 
progress to invasive carcinoma about 51%, carcinoma in situ about 40% and 
mild to moderate dysplasia about 9%. We have to do surgical excision of all 
erythroplakia lesions.   
5).ANATOMY OF TONGUE: 
Parts of oral cavity: 
It has lips, oral tongue, floor of mouth, alveolar ridge, retromolar trigone, 
hard palate and buccal mucosa.  
Tongue:  
It is a muscular structure in oral cavity, triangle in shape, root of tongue 
attached to mandible and hyoid bone. It is divided in to two parts by a V shaped 
terminal sulcus marked by circumvallate papillae, anterior two third (oral 
tongue) - part of oral cavity, posterior one third (base of tongue) –part of 
oropharynx. 
Functions: Taste, chewing, swallowing and speech. 
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Anterior two third of tongue: 
It has five parts tip, dorsal surface, ventral surface, right and left lateral borders.  
Dorsal surface of tongue: 
Papillae: Superior surface of tongue covered by mucosal folds having taste buds 
called as papillae for taste.  
1) Filiform papillae: cone shaped distributed throughout dorsum of tongue 
2) Fungiform papillae: round shaped predominantly in the border. 
3) Circumvallate papillae: cylindrical shaped in 8-12 in number arranged in 
signal V shaped line anterior to terminal sulcus. 
4) Foliate papillae: Linear shaped border of tongue near terminal sulcus. 
Ventral surface of tongue:  
Frenulum: tongue is divided in to right and left half by sagittal septum. 
Frenulum is median fold of mucosa overlying lower margin of sagittal septum. 
On each side of frenulum lingual veins present. 
Pharyngeal surface: base of tongue - sub mucosal lymphoid tissue which forms 
the lingual tonsil. 
Muscles:  
Intrinsic muscle originate and inserted within the substance of tongue. 
They are responsible for the shape of tongue. Extrinsic muscle originate from 
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structures outside tongue and inserted in to the tongue. They are responsible for 
movement of tongue and tumour infiltrated causes ankyloglossia. 
 
Figure shows Extrinsic muscles of the tongue 
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Figure shows Intrinsic muscles of the tongue 
Muscles of tongue: 
Muscles Origin insertion innervation Functions 
Intrinsic muscles 
Superior longitudinal Base of tongue 
and median 
septum 
 Hypoglossal 
nerve (XII)  
Shorten 
tongue, curl 
tip and 
sides 
Inferior longitudinal Root of tongue Apex of 
tongue 
Hypoglossal 
nerve (XII) 
Shorten 
tongue, 
uncurls tip 
and turns 
down 
Transverse Median septum Lateral 
border 
Hypoglossal 
nerve (XII) 
Narrow and 
elongates 
Vertical Dorsum of 
tongue 
Ventral 
region  
Hypoglossal 
nerve (XII) 
Flatten and 
widens 
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Muscles 
Extrinsic muscle 
Origin insertion innervation Functions 
Genioglossus Mandible(Mental 
tubercle) 
Entire 
tongue 
and 
hyoid 
bone 
Hypoglossal 
nerve (XII) 
Protrusion 
Hyoglossus Hyoid bone( 
greater horn) 
Lateral 
surface 
Hypoglossal 
nerve (XII) 
Depression  
Styloglossus Styloid process  Lateral 
surface 
Hypoglossal 
nerve (XII) 
Retraction 
Palatoglossus Palatine 
aponeurosis 
Lateral 
border 
Vagus 
nerve(X) 
Swallowing  
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Arterial supply:  
Lingual artery: it is a major artery of tongue, originate from external carotid 
artery. Tonsilar and ascending pharyngeal arteries also supplies oral tongue. 
Venous drainage:  
Deep lingual vein: it is visible in ventral surface of tongue. It ends in to internal 
jugular vein. Dorsal lingual vein also drains from tongue and ends in to internal 
jugular vein. 
Nerve supply: 
Motor supply: All intrinsic and extrinsic muscles are innervated  by hypoglossal 
nerve expect patatoglossus is innervated by vagus nerve. 
Lymphatic drainage:  
It has five primary level. 
Level I: IA- sub mental and IB- submandibular node. 
Level II: Upper jugular group of lymph nodes. 
Level III: Mid jugular group of lymph nodes. 
Level IV: Inferior jugular group of lymph nodes (Supraclavicular lymph node).  
Level V: Posterior triangle group of lymph nodes. 
Lymphatic drainage of tongue:  
Anterior tongue drains in to sub mental (level IA). 
Lateral border of tongue drains in to submandibular nodes (level IB) and upper 
17 
 
jugular group of lymph nodes (level II). 
Posterior tongue drains in to upper jugular group of lymph nodes (level II). 
Tongue is midline structure it cause bilateral lymph node metastasis. 
Skip metastasis: some patient will get level IV lymph node metastasis without 
involving level I, II and III. 
Salivary glands: parotid gland, sub mandibular gland and sub lingual gland. 
Mandible: It has ramus and body ramus has medial surface, lateral surface, 
condylar process and coronoid process. Lateral surface of ramus provide 
attachment to massticator muscle. 
Posterior and inferior border intersect to form angle of mandible. 
Coronoid process flat triangle process at the junction of superior and anterior 
border provides attachment for temporalis muscle. Condylar process at the 
junction of posterior and superior border, has two parts head and neck. Head 
form tempromandibular joint, neck provides attachment for lateral pterygoid 
muscle. 
Medial surface from lateral wall of infrotemproal fossa provides 
attachment to medial pterygoid muscle, it has mandibular foram, inferior 
alveolar nerve passed through it. 
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Temporo-mandibluar joint: 
It mandible articulate with temporal bone. When tumour infiltrates TM 
joint patients cannot open mouth. It will cause trismus. Its difficult assess the 
oral cavity with trismus.  
 
STAGING: 
T 
stage 
Description 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension  
T2 Tumour more than 2 cm but less than 4 cm in greatest dimension 
T3 Tumour more than 4 cm in greatest dimension 
T4a Tumour invades adjacent structures. Eg. cortical bone, 
deep(extrinsic)muscles of  tongue ( genioglossus, hyoglossus, 
palatoglossus and styloglossus), maxillary sinus and skin of face. 
T4b Tumour invades masticator space, pterygoid plate, or skull base or 
encases carotid artery.  
 
19 
 
 
 
 
 
 
  
N 
stage 
Description 
Nx Regional lymph node cannot be assessed  
N0 No regional lymph node metastasis 
N1 Metastasis to a single ipsilateral lymph node, 3 cm or less in 
greatest dimension  
N2a Metastasis to a single ipsilateral lymph node, > 3 cm but < 6 
cm in greatest dimension 
N2b Metastasis to multiple ipsilateral lymph node, not more than 
6 cm in greatest dimension 
N2c Metastasis to bilateral or contralateral lymph node, not more 
than 6 cm in greatest dimension   
N3 Metastasis to a lymph node more than 6 cm in greatest 
dimension   
M stage Description 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
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Figure shows T4a tongue lesion with ankyloglassia  
Stage group TNM stage 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0, T1 N1 M0, T2 N1 M0 or T3 N1 M0 
Iva T4a N0 M0, T4a N1 M0, T4a N2 M0, T1 N2 M0, T2 N2 
M0, T3 N2 M0 or T4a N2 M0 
IVb Any T N3 M0, T4b any N M0 
IVc Any T any N M1 
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ORAL CAVITY EXAMINATION:  
Simple visual inspection:  
We have to see tongue surface for description of the lesion (ulcerative, 
proliferative, exophytic, endophytic, fungating tumour) and mobility for muscle 
infiltration or hypoglossal nerve damage.  
Palpation: 
We can demonstrate the three dimension view of tumour, consistency and 
tongue fixation.  Tumour in tongue starts as small painless ulcer than progress 
to invade the muscle of tongue. Squamous cell carcinoma of tongue commonly 
present in lateral border of tongue. Bimanual examination of oral cavity will 
assess the depth of invasion of tongue tumour. 
Examination of head and neck cancer: it includes inspection and 
palpation of skin over face, scalp, oral cavity, nasal cavity, nasopharynx, ear, 
oropharynx, hypo pharynx and larynx. Than examination of cervical lymph 
nodes and cranial nerves. Tumour around 30% to 40% will has cervical lymph 
node metastasis. Patients die due to uncontrolled local disease with 
haemorrhage and aspiration. Distant metastasis is rarely seen before death. 19% 
patients may developed second malignancy in upper aero-digestive track which 
is attributed to “Field cancerization”.(13)  
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6).INVESTIGATION: 
Basic 
1) Routine blood investigation, 
2) Viral markers,  
3) ECG 
Diagnostic  
1) Biopsy from tumour 
Staging  
1) Endoscopy (Direct laryngoscopy and pharyngoscopy)  
2) X ray chest PA view  
3) CT scan head and neck.  
4) MR image head and neck. 
5) PET CT scan 
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7).TREATMENT: 
Curative intent of treatment 
Surgery is main modality of treatment for early stage carcinoma tongue. 
Early stage disease treated with surgically with adequate margins followed by 
adjuvant treatment depends upon histopathalogically.  
Late stage disease is approached with multimodality treatments 
(Surgery, radiation and chemotherapy).   
Ultimate aim of treatment: 
        1) Cure the cancer, 
        2) Restore the function 
        3) Minimize the complication of treatment 
        4) Prevent metastasis.  
  Selection of single or combined treatment modality depends on stage, 
size and site of the tumour.  Multidisciplinary team assessment should be done 
before starting treatment of tongue cancer. It includes surgical oncologist, 
medical oncologist, radiation oncologist, nursing staff, dentist, speech therapist, 
dietician and counsellor for family & social support. 
  NCCN (National Comprehensive Cancer Network) recommend early 
stage lesion will treated with single modality of treatment (surgery or radiation). 
Advance stage lesion treated with combined modality treatment.  
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Factors affecting treatment modality:  
          1) Location of the tumour, 
          2) Size of the tumour, 
          3) Cervical lymphadenopathy, 
          4) Histology 
          5) Previous treatment  
          6) Age and comorbidity 
          7) Socio-economic status.  
Early stage disease (Stage I, Stage II): 
Surgery alone: T1- Local excision with margin, T2- Partial glossectomy 
Brachytherapy alone: Hairpin technique, Plastic tube loop technique 
Surgery preferred over brachytherapy in  
          1) Bone involvement  
2) Melanoma 
3) Adenocarcinoma  
4) Tip of the tongue lesion 
5) Tumour surrounding by pre malignant lesion 
6) Syphilitic glossitis.              
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ADVANCED STAGE DISEASE: 
Surgery: 
Subtotal or total glossectomy 
Marginal/segmental mandibulectomy 
With free tissue transfer or regional pedicled flaps 
 Approach:  
Median or para-median mandibulotomy, Trans-cervical 
Management of Neck: 
Primary lesion <2 mm-neck is managed expectantly 
Larger lesion (including N0)-Selective neck dissection of levels I to IV 
Lesions close to, or involving the mid line- Bilateral neck dissection 
Postoperative RT indications: it is decrease local recurrence  
1. Close or positive margins,  
2. Extra-capsular invasion,   
3. Bone invasion,  
4. Pathological node positive disease, 
5. Lymphvascular and perineural invasion. 
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RADIATION: 
External Beam Radiotherapy upto 40 Gy followed interstitial 
brachytherapy. Decroix and Ghissein study showed combine external beam 
radiation and brachytherapy to be beneficial (14) 
Concurrent chemo-radiotherapy:  
Concurrent chemo-radiation will increase the overall survival in locally 
advanced head and neck cancer is about 5% and absolute benefit in survival 8% 
in five years.(15)  
Salvage surgery:  
It is the second attempt at cure after definite treatment or final attempt for 
cure in recurrent disease following surgery, radiation and chemo-radiation. It is 
only cure option available and mainly final curative attempt.  
Palliative intent of treatment:  
Patients with more advanced disease not curable disease will be treated 
with palliative to reduce the symptoms (like pain, bleeding and reduce the 
burden of the disease). It may be surgery, radiation and chemotherapy.  
Radiation used to relive the pain, bleeding as in palliative treatment. 
Chemotherapy used in metastatic disease. Surgery is mainly used to debulk the 
tumour size and reduce the burden of disease  
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SURGERY: 
Selecting the type, approach and extend of surgery depends on size, site 
and depth of the infiltration and proximity of tumour from mandible or maxilla, 
supine Position: 30 degree angle and anaesthesia.  
Anaesthesia:  
Small lesion are excised with local anaesthesia. 
Larger lesion require General anaesthesia with Naso-tracheal tube intubation. 
 Surgical approach: 
1. Trans-oral, 
2. Lower cheek flap 
3. Mandubulotomy 
4. Trans cervical 
With  
1) Healing by secondary intension, 
2) Primary closure,  
3) Split thickness skin grafts 
4) Free tissue transfer or regional pedicled flaps 
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RADIATION THERAPY: 
Radiation treatment can be given as teletherapy, brachytherapy and 
internal therapy.  
Mechanism of action of Radiation:  
Radiation will have two types of action, Direct action and indirect action. 
Direct action is fast moving electron interact direct with DNA molecule and 
cause DNA damage. Indirect action is fast moving electron will interact with 
other atoms or molecules in the cell. This will produce free radicals and free 
radical will cause DNA damage. Radiation will produce cell DNA damage by 
double-strand or single-strand breaks. Double strand breaks will leads to cell 
death. Single strand breaks will cause sub lethal DNA damage, it may repair by 
themselves. Before repair that cell will undergone one more single-strand break 
than this may leads to cell death. But the repair mechanism is superior in normal 
cell compared to cancer cells. Cell death means cells unable to divide 
furthermore and cause growth and spread of disease. Chromosomal aberration 
will leads to cell death while they attempt to divide after lethal dose of radiation 
(mitotic cell death).   
Aim of the radiation is to deliver precise measured dose to the target 
volume and minimal damage to the normal surrounding tissue.  
 
29 
 
BRACHYTHERAPY:  
It is form of radiotherapy where the source of the radiation is kept very 
close to the tumour or actually implanted in to the tumour. Iridium-192 is 
commonly using radioactive source in most of the canters. It has low photon 
energy makes protection easier than the Radium or Cesium-137. It gives high 
dose to tumour by a short period of time and we can spear adjacent normal 
tissue. Brachytherapy gives the benefit of function preservation, which is 
achieved through tissue preservation. Local control rates are 85% which are on 
par with that achieved by surgery.  Local control rates decrease with increasing 
tumour size. (16) 
Brachytherapy techniques in tongue:  
1) Hairpin technique: 
Implant is in the shape of hairpin, the two limbs are 12 mm apart and 6 
cm in length. This forms a double plan. Single plan implantation is not 
preferred as it does not cover deeper parts. Stainless steel slotted hairpin 
guides are inserted under general anaesthesia. First anterior most and 
posterior most hairpin guides are implanted and later the required number 
of guides are incorporated between them, with a 12 mm gap between 
them. The limbs are cut depending upon the tumour depth. Top of the 
tumour is adequately covered by the bridge of the hairpin. In order to 
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cover bottom adequately limb of the hairpin should be longer than the 
tumour.   
2) Plastic tube loop technique:  
It is used for larger volume tumour difficult to cover with hairpin 
implants.  Plastic tubes is formed in to a loop, this also a two plan 
implant. Stainless steel guide needles are pushed into the tumour from the 
skin below in jaw line. 
Brachytherapy Vs External Beam Radiation Therapy (EBRT) 
Local control rates are suboptimal in EBRT in contrast to brachytherapy 
LDR Vs HDR brachytherapy: 
HDR brachytherapy schedule- 59 Gy in 6 Gy twice daily compared to                       
LDR brachytherapy schedule- 61 Gy over 5 to 6 days showed inferior local 
control rates with HDR (T1: 85% Vs 64%, T2: 71% Vs 38%) (17) 
 
Figure shows Brachytherapy planning for carcinoma tongue.  
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EXTERNAL BEAM RADIATION THERAPY 
It is a modality of radiation delivery in which the source of radiation is at 
a distance from the human body. The radiation source may be a radioactive 
nuclide, Cobalt 60 emitting Gamma rays, is used presently, or it may be X-rays 
Produced by a Linear Accelerator, Electrons, protons, heavy charged particles 
etc. Accuracy of treatment delivery is of utmost importance. 
Positioning the patient: 
Patient in supine position, straight and neck extended. We have to place 
custom-made mouth bite to depress the tongue. Because we have to avoid 
radiation dose to hard palate and parotid glands. Than patient should be 
immobilized with thermoplastic mould or perspex. It is helped to fix the well-
defined position to treat the patient.  
If a patient is having short neck, both shoulders should be depressed by 
tensioning device to loop the feet. Because we have to treat whole neck region.  
Effective immobilization will reduce setup error. 
Radiation techniques: 
1) 2D conventional technique 
2) 3D conformal technique 
3) IMRT technique 
4) Rapid arc technique. 
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2D CONVENTIONAL TECHNIQUE: 
Target volume includes primary tumour with 2 cm margin and ipsi lateral 
submandibular and upper deep cervical nodes. 
Early lesion in lateral tongue is treated using anterior and lateral wedged 
fields, this gives homogenous dose distribution with sparing of contralateral oral 
cavity and spinal cord. For large tumours near or crossing midline two opposing 
lateral fields are used. Anterior and lateral wedged fields produce less mucositis 
and xerostomia compared to two opposing lateral fields used in extensive 
tumour. 
 
 
Figure shows 2D wedge field technique for carcinoma tongue  
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RT field borders in two opposing lateral fields:  
Superior border: 2 cm above the primary lesion, 
Inferior border: below hyoid bone, 
Anterior border: 2 cm front of primary tumour (usually in front of mandible), 
Posterior border: back to the vertebral corpuses. 
 
Figure shows 2D planning with MLC shielding of lateral field 
Supraclavicular field border: 
Superior border: inferior border of lateral fields, 
Inferior border: bottom supraclavicular joint, 
Lateral border: including medial two third of clavicle.  
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Figure shows 2D planning with MLC shielding of anterior field 
After completing 45Gy of external beam radiation in two opposing lateral fields 
the posterior border is shifted anterior to spinal cord to spare the spinal cord.     
 
Figure shows 2D off cord planning with MLC shielding of lateral field  
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3D CONFORMAL TECHNIQUE: 
In conformal technique target volume is defined with three dimensions 
view for contouring purpose. It has multiple beams because to reduce the 
normal tissue toxicity and confined dose to the target alone. But concavity not 
archived in conformal technique. Setup errors also present in conformal 
technique.  Contouring is drawing in CT scan in slice by slice and exact 
conformity we can achieve. Beam shaping done with multi-leaf collimators 
(MLC).  It usually has 4 – 6 beam angles. It is 3Dinemtional images will give 
precise treatment planning. In this no need to change the blocks during the 
treatment. Intensity of the beam is uniform.  
Planning CT scan: 
CT scan should be done from base of skull to arch of aorta with supine 
position of the patient with immobilization thermoplastic mould. In the CT scan 
will send to planning system, there is got registered in planning system, than we 
have do contouring the structure of the patients. This CT scan will be in axial 
Cuts depending upon the technique we can take the slices from 0.25 cm, 0.5 cm 
and 0.75 cm.       
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ICRU Volumes for contouring: 
Gross Tumour Volume (GTV):  
It is grossly demonstrable tumour, macroscopic lesion. Tumour id visible, 
palpable and demonstrable in imaging.  
Clinical Target Volume (CTV): 
It is demonstrable tumour and any other surrounding tissues with 
presumed tumour. It delineate  
Planning Target Volume (PTV): 
In this volume that includes CTV, setup margin and setup uncertainties.   
Organ at risk (OAR):  
Spinal cord, brain stem, brain, contralateral parotid, larynx and inferior 
constructor. Tolerance doses are given in Table 4 
OAR Tolerance dose 
Spinal cord Max - 45Gy 
Brain stem Max – 54Gy 
Brain 60Gy point dose 
Contralateral parotid Mean dose 26Gy 
Larynx Mean dose 40Gy 
Inferior constrictor Max 50Gy 
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IMRT (INTENSITY-MODULATED RADIATION THERAPY): 
Non uniform fluence of dose distributed to the patient with any given 
position of treatment beam to optimize the composite dose distribution. It also 
called as Inverse planning technique. It is to treat a patient with multiple number 
of beam direction non uniform fluence, it optimize high dose to target volume 
and low dose to surrounding normal tissue. In which we can achieve good dose 
conformity and steep dose gradient outside the target. It has two MLC window 
technique 1) dynamic MLC delivery, 2) step and shoot delivery. 
Considerable factors in IMRT is increased cost, increased worked, 
increased treatment time/delivery, high integral dose, increased risk of second 
primary and low dose hypersensitivity. In head and neck cancers IMRT will 
spear major salivary glands and reduce xerostomia. Geographic miss due to 
improper positioning of the patient, organ motion and inadequate target 
delineation.      
Limitation of IMRT: 
Most dose distribution not physically achieved, distortion of internal 
anatomy, intrafraction motion and interfraction variation.  
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ALTERED FRACTIONATION SCHEDULES: 
During conventional fractionation using conformal and IMRT techniques 
are reduce normal tissue toxicities. But improving loco-regional control will 
achieve by increasing dose to tumour should be needed. In prolonged treatment 
time the tumour cell allow for repopulation. For that few newer fractionation 
schedule were tried. It is alerted fractionation. 
Hyper-fractionation:  
It is increase daily fraction with reduce the daily dose, which will leads to 
decrease the overall treatment time. It will reduce late toxicities, increase 
tumour control and slightly increase acute toxicities. 
Accelerated fractionation: 
It is increase daily fractions without alter the daily dose and decrease the 
overall treatment time. It will increase the local control, slight increase acute 
and late toxicities.  
Hypo-fractionation: 
It is decrease total fractionation along with increase the daily dose. It 
decrease overall treatment time and increase local control. Acute toxicities are 
same with increase late toxicities.  
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Accelerated repopulation: 
The cells are treated with cytotoxic agents (e.g Radiation) can trigger the 
surviving cells to divide faster than before. Analysis suggested that accelerated 
repopulation starts in human cancer cells about 4 weeks after starting radiation.  
So dose increment about 60 cGy/fraction will compensate the accelerated 
repopulation.  
Pre-treatment doubling time for head and neck cancers is 30 to 60 days, 
but after radiation starts the doubling time is reduced to 3 - 5 days. In head and 
neck cancers each day delay during treatment will reduce the local control about 
from 0.4 to 2.5%. It is better to delay initiation of treatment than introduce delay 
during treatment. (18)   
CONCOMITANT BOOST:  
It is during the conventional fractionation boost dose is given in last two 
weeks radiation. It will counteract the accelerated repopulation.  In boost 
treatment duration daily dose will decrease and gap between two fractions is 6 
hour.  It is increase loco-regional control and disease free survival. It will leads 
to more severe acute toxicities and no effect on late toxicities. 
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Conventional 
fractionation 
Hyper 
fractionation 
Accelerated 
fractionation 
Concomitant 
Boost 
Total no of 
fractionation 
30 
fractionation Increased 
Same as 
conventional Increased 
Dose/ # 200cGy/ # Decreased 
Same as 
conventional Decreased 
Overall time  6 weeks same/increased 
Same as 
conventional Decreased 
No of #/day 1 > 1 fractionation Increased 
> 1 # in last 
2weeks 
Total dose 60Gy Increased Decreased Decreased 
 
SIMULTANEOUS INTEGRATED BOOST-INTENSITY MODULATED 
                             RADIOTHERAPY (SIB-IMRT) 
It is intuitive radiation technique. It will deliver extra boost 
simultaneously along with normal fractionation. It will increase to dose to target 
sub-volumes and reduce dose to critical structures. IMRT is using computer-
optimized intensity distribution are controlled by dynamic MLCs will delivered 
multiple beam along with simultaneously irradiating nearby tissue in different 
dose in single treatment session. This technique will allows for improved dose 
conformity, excellent dose homogeneity within the target volumes, and 
conformal avoidance of adjacent critical normal tissues throughout the 
treatment course. Using this approach, the fractional dose delivered to gross 
tumour will be increased, at the same time the radiation doses and dose 
schedules are adequate for tumour control in marginal tissues and clinically 
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uninvolved lymph nodes are preserved. This approach is called as Simultaneous 
Integrated Boost (SIB). (19, 20, 21, 22, 23, 24, 25, 26) 
 
Acute toxicities:  
Mucositis:  
It is most common side effects of radiation and chemotherapy, But short 
term side effect. It depends on type ionizing radiation, dose of RT, rate of RT 
delivered. It cause pain which needs stop therapy to mucositis to heal. It is due 
to mitotic death of cells.   
RTOG grading of Mucositis: 
1)  Grade I- Injection or mild pain. 
2) Grade II- Patchy mucositis and moderate pain.  
3)  Grade III- Confluent fibrious mucositis and severe pain. 
4)  Grade IV- Ulceration, haemorrhage and necrosis. 
 
RTOG grading of Dermatitis:  
1) Grade I- Faint or dull erythema, epilation, 
2) Grade II- Bright erythema, patchy moist desquamation,  
3) Grade III- Confluent moist desquamation other than skinfolds,  
4) Grade IV- Ulceration, haemorrhage and necrosis. 
42 
 
 
RTOG grading of Dysphagia:  
1) Grade I- Mild dysphagia may require soft diet, 
2) Grade II- Moderate dysphagia may require liquid diet, 
3) Grade III- Severe dysphagia may require IV fluids, NG tube insertion. 
4) Grade IV- complete obstruction, ulceration, perforation and fistula.   
 
Late toxicities:  
       1) Xerostomia 
       2) Dysphagia 
       3) Taste alterations 
       4) Osteoradionecrosis  
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CHEMOTHERAPY:  
Cisplatin (cis-diamminedichloroplatinum) (CDDP) 
It is used in wide variety of cancers, it is a prototype drug and alkylating 
agent. It has high affinity to electrons so it increase sensitive of radiation. 
Mechanism of action: 
          1) Inhibition of DNA synthesis,  
          2) Inhibition of transcription elongation by DNA cross links, 
          3) Inhibition of repair of radiation induced DNA damage. 
 Dose regimen: 
          1) 100 mg/m2 or 70 mg/m2 IV every 3 weekly for 3 cycles, 
          2) 40 mg/m2 IV every weekly for 6 cycles.  
Administration: 
1) Monitoring with serum creatinine, electrolyte, magnesium and 
calcium. 
2) Antiemetics: we should started with ondensetron, dexamethasone.                
3) Hydration: we have hydrate the patient with adequate Intravenous 
fluids and administration of KCL and MgSO4 infusions during delivery. 
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Toxicity:  
Dose limiting toxicity are acute renal failure, peripheral neuropathy 
(cumulative dose >400mg/m2) and ototoxicity (Dose > 100 mg/m2). Common 
side effects are severe nausea, vomiting will happened all patients, it will leads 
to electrolyte imbalance. Other common side effects are anorexia, metallic taste 
of foods, myelosuppression and sterility. Other occasional side effects are 
SIADH, cortical blindness, congestive cardiac failure and tetany.    
Indication:  
1) Unresectable squamous cell head and neck cancers, 
2) Nasopharyngeal cancer, 
3) Laryngeal cancer, 
4) Postoperative  
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II.AIM: 
To evaluate the feasibility of hybrid simultaneous integrated boost (SIB) 
technique and its efficacy in the treatment of locally advanced carcinoma 
tongue. 
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Inclusion Criteria:  
1) ECOG performance score: 0-2, 
2) Age 30-60 years, 
3) Both sexes 
4) Locally advanced carcinoma anterior 2/3rd tongue  
(T4a, N1, 2 & 3, M0), 
5) Patient is planned for definitive concurrent chemo radiation 
 (3 weekly Cisplatin 70 mg/m2)  
6) Histopathology: Squamous cell carcinoma. 
7) Non metastatic disease. 
8) Adequate blood function test, 
9) Written informed consent for the study. 
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Exclusion Criteria: 
1) Patients with poor performance status (3 & 4), 
2) Patients initially treated with Radiation therapy, Chemotherapy and 
surgery, 
3) Patients who had other histology: adenocarcinoma, melanoma and 
lymphoma. 
4) Patients with palliative intent of treatment, 
5) Patients who has not willing to participate in this study, 
6) Patients with previously diagnosed as parotid glands disorder ( e.g 
Sjogren’s syndrome)  
7) Patients with predisposing to enhancing radio sensitivity (e.g 
ataxiatelangiectasia or past/active connective tissue disorders). 
8) Uncontrolled comorbidity 
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III.MATERIAL AND METHODS:  
          All patients who came to Cancer Institute were examined 
thoroughly. Most of the patients were referred by non-oncology 
physicians. Diagnostic and staging investigations are done on outpatient 
basis. After conforming non-metastatic squamous cell carcinoma of oral 
tongue. Patient with stage IVa and IVb were enrolled in the study. Patients 
were counselled clearly about treatment modality, technique, toxicities and 
disease outcome. After getting informed consent these patients were 
enrolled into our study.  
All patients were advised about the importance of proper nutritional, 
encouraged to avoid spicy food. All patients were Counselled for strict cessation 
of smoking and/or tobacco chewing habits, Clearly explained that smoking or 
tobacco chewing during treatment will reduce the treatment outcome and wil 
also increase the risk of occurrence of second primary in aero-digestive track. . 
They were explained about the importance of oral hygiene All patients 
underwent dental examination and if needed dental extraction done.  Patients 
were all admitted in ward.  
Thermoplastic mould was done to immobilise patients in supine position, 
with custom made mouth bite to depress the tongue. 
49 
 
Planning CT scan done for all patients in flat couch from base of skull to 
arch of aorta with thermoplastic mould.  
Treatment: 
All patients were planned for concurrent chemo-radiation. Chemotherapy 
schedule was 70 mg/m2 Cisplatin in day 1, 22 and 43.  
Radiation was designed to be delivered in two phases. All patients were 
treated with 6 MV photons in 600c unit at our institute.  
Treatment was delivered in two phases as planned. 
Phase I: 
  Patient were treated with 6 MV X-ray beam therapy to deliver a Total 
Dose of 36Gy using conformal technique with 200cGy daily dose per fraction 
for 5 days/week over 3.5 week 
In this phase PTV includes primary tumour and bilateral whole neck 
nodes along with setup error margins. This area received TD 36Gy in phase I. 
After completion 36Gy all patients were underwent re-planning. A repeat 
Mould and repeat CT scan. 
Phase II:  
It has two PTV’s, the high risk PTV (residual primary and residual neck 
nodes) and the low risk PTV (the entire PTV contoured in phase I excluding the 
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cord) were contoured. Patients were treated with 6 MV X-ray beam therapy 
using IMRT technique. 
  A Total Dose of 24Gy as 240cGy/day to the high risk PTV and a Total 
Dose of 20Gy as 200cGy/day to the low risk PTV was delivered simultaneously 
in 10 days over 2 weeks.  
Chemotherapy delivered was three weekly Cisplatin. 
These patients were compared with 10 matched control patients treated in 
2015 with conformal technique TD 60Gy (200cGy/day), 5 days per week, over 
6 - 7 weeks concurrent with chemotherapy. 
During the treatment all patients are advised to take a proper nutritional 
support. They are advised to do sodium bicarbonate mouth wash 6-8 times per 
day, to avoid tooth brushing in order avoid mucosal injury. All patients were 
advised to have non-spicy soft bland easily digestible high protein diet with 
added salt. They were all advised to take more vegetables, more water intake to 
reduce renal toxicity by Cisplatin. They were also told to avoid hot or chilled 
food as it may aggravate mucositis. Multivitamins and antioxidants were given 
daily for all patient. Patients were started on chymerol forte at around the end of 
third week of treatment. Amifostine is not usually administered at our institute. 
During the treatment time good psychological support were given to all patient 
and moral support also given. 
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Figure shows 3D representation of PTV in 3D conformal technique 
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Figure shows dose distribution of 3DCRT plan (Sagittal plane) 
 
Figure shows dose distribution of 3DCRT plan (Transverse plane) 
 
 
 
Figure shows dose distribution of 3DCRT plan (Coronal plane) 
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Figure shows 3D representation of PTV in SIB-IMRT plan 
 
 
 
Figure shows dose distribution of SIB-IMRT plan (Transverse plane) 
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Figure shows dose distribution of SIB-IMRT plan (Coronal plane) 
 
 
 
Figure shows dose distribution of SIB-IMRT plan (Sagittal plane) 
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Toxicity Assessment and management: 
All patients were assessed for tumour response for primary, nodal 
region and acute toxicity during the treatment period on weekly basis.  
During the radiation treatment patients developed acute toxicity like 
mucositis, dermatitis and dysphagia. These patients advised for 
conservative management. Patients with mucositis were advised for 
frequent mouth wash, lignocaine viscous gel/Mucaine gel for pain relief. 
Opioids and NSAIDS in the form of tramadol or ibuprofen along with 
paracetmol were used for relief of mucositis/dermatitis induced pain when 
ever needed. Patients who developed grade III acute toxicities advised for 
Naso-gastric tube insertion for better nutritional support. 
Before delivering chemotherapy all patient’s complete blood count, 
renal function test, liver function test and serum electrolytes was checked. 
Chemotherapy was delivered only if all blood investigation were normal, 
patient vitals are stable and hydration was adequate. If investigation are de-
arranged patient was admitted to ward and conservative management was 
given to that patients along with pending that schedule of chemotherapy or 
radiation.   
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During treatment weekly twice white blood cell count was checked 
for all patients.  
Response assessment: 
Patient response to treatment is assessed 6 weeks after completion of 
treatment according to World health organization criteria for solid tumour.  
Local disease control is evaluated by clinical examination and imaging and 
biopsy is done whenever necessary. For each follow up review complete 
physical examination, response assessment and toxicities assessment were 
done.   
Response Evaluation Criteria in Solid Tumours (RECIST) 
1. Complete response (CR): disappearance of all known disease by two 
observations not less than four weeks apart. 
2. Partial response (PR): 50 % or more decrease the tumour size by two 
observations not less than four weeks apart. 
3. No changes (NC): 50 % decrease in tumour size not assessed and 
more than 25% decrease in tumour size assessed. 
4. Progressive disease (PD): 25 % more increase the tumour size or 
new lesion appearance.   
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IV.RESULTS:  
          From September 2015 to august 2016, there were total    number of 
case diagnosed with carcinoma tongue, were stage IV, Twelve patients fit 
in to the inclusion criteria. These twelve patients with locally advanced 
carcinoma tongue stage IVA and IVB were enrolled in to study after taking 
a written informed consent. But, one patient had tumour bleeding at 6Gy 
itself so patient was treated with haemostatic radiation to tongue TD 
500cGy in two fractionation. Hence, patient in not included in this study. 
Another one patient had progressive disease in the form of nodal region 
ulcerated and development of post auricular nodes was treated with 
palliative radiation. Hence this patient also not included in this study. Total 
ten patients were assessed in the study. All the 10 patient completed the 
treatment. 
Patient characteristics: 
          Median age of 43.7years (range of 39 to 65 years), all are male 
patients diagnosed to have stage IVa carcinoma tongue. In this patients 4 
patients were smoker and 5 were chewing, one patient having both the 
habits of smoking and chewing. Size of primary lesion ranging from 5 x 3 
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cm to 8 x 7 cm. Seven patients had tumour in the ventral surface of the 
tongue, two patients had extensive tumour occupying entire tongue, one 
patients alone tumour was limited to lateral border. Clinically two patients 
had no neck nodes palpable, two patients had ipsi lateral single node < 3 
cm, one patient had ipsi lateral node 4cm, four patients had multiple ipsi 
lateral nodes < 6 cm, and one patients had bilateral neck nodes < 6 cm. 
Acute toxicity:  
         During course of treatment at 30Gy two patients developed Grade I 
mucositis and four patients had grade II mucositis who progresses to have 
Grade III mucositis at the end of first phase of treatment requiring 
treatment break. 
         At the end of first phase four patients had grade I mucositis, two 
patients had grade II mucositis and four patients had grade III mucositis. 
At the end of treatment two patients each developed Grade I, II and III 
mucositis. None had grade IV mucositis. Two patients developed oral 
candidiasis were treated with local anti-fungal. 
         Five patients had Grade II-III dysphagia requiring nutrition support 
in the form of Ryles tube and Intravenous fluids.  
         Six patients had dry desquamation of skin field area, two patients had 
moderate dermatitis at the end of treatment. 
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         At some points of treatment only two patients developed grade III 
neutropenia with nadir ANC-900/Cu mm.  These patients are managed 
with prophylactic IV antibiotics. None of the patient developed febrile 
neutropenia. These two patients received Inj. GCSF (Granulocyte colony 
stimulating factor) for 5 days. During this time patient was treated with 
radiation. 
Treatment break: 
         Out of ten patients three patients had a treatment break of more than 
10 days owing to Grade III mucositis, 2 patients also had Grade III 
neutropenia. All patient put together had a mean treatment break 7.2 days 
ranging from 3 to 12 days.  
Completion of chemotherapy: 
         Out of the ten patients five patients all the three cycles of 
chemotherapy on scheduled time. Four patients had only two cycles 
chemotherapy, one patient had only one cycle of chemotherapy.  None of 
the patient had other Cisplatin complications like ototoxicity, 
nephrotoxicity and peripheral neuropathy other complication.  
Treatment results: 
         Out of ten patients four patient had a satisfactory primary tumour 
regression, eight patient had complete nodal regression. At 3 months after 
60 
 
the end of treatment all four patients continue to have good loco-regional   
control, one patient had static response and remaining five patients had 
residual disease. 
Follow up:  
         All patients were reviewed after 6 weeks for assessing the first follow 
up. Then all patients were regular assessed by monthly once for one year. 
After that patients will be follow up by three months once for two years, 
than six months once for two more years after that annual follow up.   
 
Retrospective Control group: 
        Retrospective data of patients diagnosed as carcinoma tongue and 
treated with concurrent chemo-radiation using conformal technique in 
conventional fractionation in our institute in the year 2015 was collected. 
Of these, ten patients matched for age, stage, site of tumour were taken as 
control group and analysed in detail and compared with the study group.  
 
Comparison: 
         In age distribution analysis younger age (< 40 years) patients are well 
response to treatment compared to old age (> 50 years) patients in both 
study group and control group. Loco-regional control are more in young 
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age patients.  Elderly age patients are not tolerate the chemotherapy and 
more acute toxicities and treatment breaks are more in both groups.  
 
Loco-regional response with respect to different age group: 
AGE 
Years  
Study group 
(10) 
LR response  
Control 
group (10) 
LR response 
< 40 4 2 3 2 
40-50 4 2 4 1 
50-60 1 0 2 0 
>60 1 0 1 0 
 
         In study group all patients are having smoking /or tobacco chewing 
habits. Tobacco chewing having more incidence of oral cavity cancer 
compared smoking habit. Compare to both group smoker are less response 
to treatment compared with tobacco chewer. 
 Loco-regional control with respect to habits: 
HABITS 
Study 
group (10) 
LR response  
Control 
group (10) 
LR response 
Smoking 4 1 2 0 
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Chewing 5 3 5 2 
No habits 0 0 1 1 
Both habits 1 0 2 0 
 
         In study group seven patients are ventral surface of tongue, two 
patients are entire tongue and one patient is lateral surface involvement. In 
control group   six patients are entire tongue and four patients are ventral 
surface involvement present. Both entire tongue and ventral surface tongue 
are poor prognosis patients. Compared in both ventral surface tongue 
patients response to treatment is well on both group. Ventral surface 
tongue we cannot assess the deeper invasion of the tumour. Hence it is 
consider bad prognosis.  
 
Loco-regional control with respect to site of the lesion  
 
0 
1 
2 
3 
4 
5 
6 
7 
Study group (10) LR response  Control group (10) LR response 
SITE OF THE LESION 
Entire tongue Ventral surface Lateral surface 
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          In our study nodal stage more than N2b not response well compared 
to nodal stage N1 and N2a. The study group having two patients are N1 
node and one patient is N2a node were responded well to the treatment. 
Among the four patient were having N2b nodes three patient responded 
well. In control group two patients having N1 node and two patients were 
having N2c were responded well. Along five patients having N2b node 
two patients only responded only. 
 
 
NODE 
Study 
group (10) 
Node regression 
Control 
group (10) 
Node regression 
N0 2 2 0 0 
N1 2 2 2 2 
N2a 1 1 0 0 
N2b 4 3 5 2 
N2c 1 0 2 1 
N3 0 0 1 0 
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          In nodal response is 80% vs 50% (p=0.16) in study group and 
control group respectively 
NODE 
Study 
group (10) 
LR response  
Control 
group (10) 
LR response 
N0 2 0 0 0 
N1 2 2 2 0 
N2a 1 1 0 0 
N2b 4 1 5 2 
N2c 1 0 2 1 
N3 0 0 1 0 
 
 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
study group (10) control group (10) 
NODAL RESPONSE 
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Treatment breaks: 
          Treatment breaks are comparable in both groups. There are four 
patient having < 5 days treatment in both group for which response is one 
and two patients respectively. In 5 – 10 days treatment break were three in 
study group and four in control group, among them response well were two 
patients in study group and one patient in control group. In more than 10 
days treatment break three patients in study group and two patients in 
control group, among them  in study group one patient responded well 
compared to control group none of the responded. 
 Loco-regional control with respect to treatment break:  
 
 
0 
1 
2 
3 
4 
Study group (10) LR response  Control group (10) LR response 
TREATMENT BREAKS 
< 5 days 5 – 10 days .> 10 days 
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          In comparing tumour size, small size tumours were responded well 
in both group. In contrast study group on patient had tumour size of 8 x 7 
cm tumour responded well with hybrid technique. In study group 5 cm 
tumours responded well comparable with control group. Five patients were 
having the tumour size of 6 x 5 cm in study group none the patients 
responded. Four patients were having tumour size of 6 x 4 cm in control 
group none of them responded. In study group four patients responded well 
compared to control group three were responded well. Large volume 
tumour response usually poor in both group. 
 
Loco-regional control with respect to volume of tumour 
SIZE 
Study group 
(10) 
LR response  
Control group 
(10) 
LR response 
5 x 3 cm 2 2 2 1 
5 x 5 cm 0 0 2 2 
6 x 4 cm 1 1 4 0 
6 x 5 cm 5 0 1 0 
7 x 6 cm 1 0 1 0 
8 x 7 cm 1 1 0 0 
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Loco-regional response: 
          In study group among the ten patients four responded well with 
hybrid simultaneous integrated boost technique. In control group among 
the ten patients three patients responded well. The p value is 0.639.  
          The loco-regional response is slightly better in study group 
compared to control group. But, the p value is not significant in this study 
because of poor response of the disease. 
 
 
Statistical Analysis:  
          The loco-regional response and toxicity profile was analysed by 
Kaplan-Meier method.  P value was also calculated in chi-square test. 
 
0 
1 
2 
3 
4 
study group (10) control group (10) 
LOCO-REGIONAL RESPONSE 
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V.DISCUSSION:   
Management of tongue cancer depends on extent of primary tumour and 
nodal status. The options are radical RT with or without neck dissection and 
primary surgery with or without postoperative RT.  Definitive/ Initial 
Radiotherapy has a benefit mainly due to functional preservation. Base of 
tongue tumours are more radiosensitive than oral tongue. Overall treatment time 
plays a major role in local control.    
For locally advanced head and neck cancer treated with primary 
radiation, It is believed that radiation alone is inferior therefore the current 
standard of care is concurrent chemo-radiation. Concurrent chemotherapy along 
with altered fractionation is superior in the form of loco-regional control and 
comparable toxicity profile. 
External Beam Radiotherapy up to 40Gy followed interstitial 
brachytherapy. Decroix and Ghissein study showed combine external beam 
radiation and brachytherapy to be beneficial. 
Brachytherapy gives the benefit of function preservation, which is 
achieved through tissue preservation. Local control rates are 85% which are on 
par with that achieved by surgery.  Local control rates decrease with increasing 
tumour size.  
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Using Linear-quadratic modal we can compare the radiation dose of two 
different technique by using Biologic Effectiveness Dose (BED).  
          BED = (total dose) x (relative effectiveness)  
          BED = (nd) x (1+ d/ α/β) 
For 200cGy conventional fractionation schedule for TD 60Gy  
          BED = 30 x 2 (1 + 2/10) = 72Gy 
In study group patient was treated with two phase of treatment. 
In phase I, they were treated with 200cGy per fractionation for TD of 36Gy 
over 18 fractions. The BED of this schedule is 
          BED 36 =   18 x 2 (1 + 2/10) = 43.2Gy 
In phase II, they were treated with 240cGy per fractionation for TD of 24Gy 
over 10 fractions. The BED of this schedule is  
          BED 24 =10 x 2.4 (1+ 2.4/10) = 29.76Gy. 
Total BED of the study group is 43.2 + 29.76 = 73Gy.  
In study group BED compare to control group BED is more in 1Gy.    
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HYBRID TECHNIQUE:  
Locally advanced squamous cell carcinoma of tongue cause major burden 
of disease. It needs aggressive treatment for satisfactory loco-regional control.  
Radical surgery is not feasible and more surgical morbidity. Therefore chemo-
radiation is the main modality of treatment in locally advanced tongue cancer. 
In standard fractionation schedule will achieve limited loco-regional control. 
Therefore the newer approach to evaluate the altered fractionation for better 
loco-regional control and overall survival.  In altered fractionation concomitant 
boost technique causes better loco-regional control achieved compared with 
other techniques. In this study we were attempted hybrid simultaneous 
integrated boost technique for treating locally advanced carcinoma tongue. 
RTOG 90-03 study:  
Improvement on disease free survival is 8 % in hyper-fractionation, 
accelerated concomitant boost fractionation compared to standard fractionation. 
(27) In this hyper-fractionation having high cost, more work compared to 
concomitant boost technique. There will be an inconvenience for multiple 
fractionation will leads to more acute toxicity. It will increase the workload of 
radiation treatment units, technologist, physicist and radiation oncologist. In our 
study we can escalate the dose in phase II will be like concomitant boost 
technique.  
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Accelerated repopulation:  
During end of treatment accelerated repopulation of tumour cell are more 
it will leads to tumour proliferation. In this study designed for additional dose 
given during end of treatment will compensate the accelerated repopulation. 
Concomitant boost radiation is reduce the treatment duration. It leads to 
counteract the accelerated repopulation of clonogenic cells on radiation.(28) 
 
In contrast to concomitant boost technique in this study patients were 
treated with single fractionation schedule not in concomitant boost technique 
patient was treated two fraction for 2 weeks with 6 hours gap. This will reduce 
the workload of machine and manpower especially in large volume patient 
treating radiation centres (29). In this centres we cannot treat all patients with 
advance radiation technique. Because this will consume more treatment time of 
the machine and working staffs. For that we attempted hybrid simultaneous 
integrated boost technique for locally advanced tongue cancers (30).   
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Ghoshal et al studied 216 patients with oropharyngeal cancers treated 
with concomitant boost radiation and compared with concurrent chemo-
radiation. Median treatment break was 11 days but in our study 7.3 days. 
Hospital admission needed was 54% but my study 20%. Grade III Mucositis 
were 54% comparable with standard conventional fractionation. Loco-regional 
response is 74% Vs 68% (p=0.3) and partial response were 25% and 22% 
reported (31). 
2 years disease free survival in this study is 61% (p=0.2).   
Acute toxicities Grade III mucositis were 55% and 38%.  Grade III dermatitis 
were 61% and 27%. Grade III dysphagia were 34% and 42%.    
Bhavana rai et al 60 patients of locally advanced head and neck cancer 
were compared concomitant boost chemo-radiation vs standard concurrent 
chemo-radiation. Local control for both arm had no significant difference (54% 
vs 49%) but toxicity profile were comparable. In acute toxicities Grade III 
mucositis were 43.5% and 48.2%. Grade II or more dermatitis were 78.3% and 
81.7%. Grade II or more dysphagia were 87.2% and 96.4%. Grade II or more 
weight loss were 57% and 75.2%. Compare to our study local control were 40% 
and 30%.  Acute toxicities were Grade III mucositis were 60% and 40%.  Grade 
III dermatitis were 40% and 40%. Grade III dysphagia were 20% and 30%. 
Ryles tube insertion were 50% and 50% (32). 
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Sabine Bieri et al 42 locally advanced oro-pahryngeal cancer was treated 
with concomitant boost technique from May 1991 to October 1995. Local 
control after 3 years 79% and 61% (p-0.005). Acute toxicities like Grade III 
mucositis were 78%, grade III dysphagia were 68 and 25%, ryles tube insertion 
were 68% and 14%.(33) 
In the University of Texas M.D Anderson Cancer Centre, a study was 
done with increasing fractionation after 12 days of initial radiation. It is based 
on incremental dose needed to compensate the cancer cell proliferation at near 
the end of radiation treatment (34).   
SIB: 
SIB-IMRT is more needed in busy radiation treatment centre with limited 
treatment machine and manpower. Because it is single daily treatment with 
escalating dose to target volume. This dose escalation radio biologically will 
toxicity to late responding normal tissue near or inside the GTV receiving 
higher dose. For that in this study dose escalation done towards end of therapy. 
Treatment breaks is due to acute toxicity. To overcome the repopulation during 
this treatment break. Increase dose per fraction and or number of fraction in a 
week can be increased. 
Davide et al there were 50 patients head neck cancer enrolled in this 
study, they were treated with SIB 70 and SIB 66 schedules. In SIB 70 three 
target volumes were contoured (70Gy, 60Gy and 54Gy in 33 fractions), in SIB 
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66 three target volumes were contoured (66Gy, 60Gy and 54Gy in 33 fractions).  
At two years follow up local control were 91% and overall survival rate were 
82.4%. Acute toxicities were Grade III mucositis 10%, Grade III dermatitis 6%, 
Grade III dysphagia 6% and Grade III xerostomia 4%. None of the patient had 
Grade IV toxicity. This study conclude that SIB-IMRT is safe and highly 
effective technique for treatment of head and neck cancers (35).  
Chakraborty et al there were 28 patients head and neck cancer patients 
enrolled in this study were treated with SIB 72 and SIB 66 schedules. In SIB 72 
target volumes were contoured (72Gy, 66Gy and 57Gy in 33 fraction) and in 
SIB 66(66Gy, 60Gy and 54Gy in 33 fraction). In follow up one out of 28 
patients had local recurrence. None of the patients had distant metastasis. Acute 
toxicities were Grade III mucositis 42.9%, Grade III dermatitis 14.3% and 
Grade III xerostomia 10.7%. (36)   
Concurrent chemo-radiation: 
Pignon et al meta-analysis combined 93 randomized trials (37). It showed 
concurrent chemo-radiation will increase the overall survival in  locally 
advanced head and neck cancer is about 5% and absolute benefit in survival 8% 
in five years (38,39, 40, 41). 
Limitations of our study: We selected small number of patients, stage Iva 
tongue with ventral surface and entire tongue patients,   
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VI.CONCLUSION 
Hybrid simultaneous integrated boost (SIB) technique appears to be a 
feasible technique concurrent with chemotherapy in terms of better local control 
and comparable toxicity profile. Long term follow up to assess overall survival 
is needed before definitive conclusions can be made. Definitive conclusion can 
be obtained only if large volume of primitive early disease is analysed in future. 
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